{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:11:44Z","timestamp":1763017904210,"version":"3.40.5"},"reference-count":40,"publisher":"Walter de Gruyter GmbH","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2018-0020_s_999_w2aab3b7c33b1b6b1aab1c16b1Aa\">\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p>Thyroid dysfunction (TD) was usually described in hematopoietic stem cell transplantation (HSCT) recipients who were given total body irradiation (TBI) in the conditioning regimen. Because previous studies have reported discrepant results regarding the presence of long-term thyroid complications in HSCT survivors following chemotherapy-only conditioning, we investigated the frequency of thyroid abnormalities in a series of children treated with HSCT for different disorders without TBI as part of the conditioning protocol.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2018-0020_s_998_w2aab3b7c33b1b6b1aab1c16b2Aa\">\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>We compared thyroid-stimulating hormone, free thyroxine, total triiodothyronine (TT3), anti-peroxidase (TPO Ab) and anti-thyroglobulin antibodies and thyroid volume z-score in 28 HSCT survivors and 16 healthy subjects matched for age and sex.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2018-0020_s_997_w2aab3b7c33b1b6b1aab1c16b3Aa\">\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>HSCT recipients had a higher frequency of TD and thyroid complications in total, including TD and euthyroid Hashimoto thyroiditis, compared to the control group. Patients transplanted for Hodgkin lymphoma (HL) were more likely to develop a thyroid complication compared to patients with non-malignant hematologic diseases and leukemia patients. BEAM (carmustine, etoposide, citarabin and melphalan) conditioning compared to busulfan (Bu) and fludarabine (Flu)-based regimens and autologous compared to allogenic grafting were associated with a higher prevalence of TD in our study. HSCT survivors had higher mean serum TT3 levels. A multivariate analysis revealed that autologous (auto)-HSCT recipients had higher mean serum titers of TPO Ab compared to allogenic (allo)-HSCT recipients and controls and the mean thyroid volume z-score was significantly higher in controls compared to auto-\/allo-HSCT survivors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2018-0020_s_996_w2aab3b7c33b1b6b1aab1c16b4Aa\">\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>We identified a 35.7% prevalence of thyroid abnormalities, emphasizing the need for a long-term surveillance of thyroid function and morphology even in this group of patients who were not exposed to TBI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2018-0020","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T07:26:03Z","timestamp":1533885963000},"page":"869-878","source":"Crossref","is-referenced-by-count":12,"title":["Long-term thyroid disorders in pediatric survivors of hematopoietic stem cell transplantation after chemotherapy-only conditioning"],"prefix":"10.1515","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3564-7376","authenticated-orcid":false,"given":"Luminita N.","family":"Cima","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Carol Davila University of Medicine and Pharmacy , 37 Dionisie Lupu Street , 030167 Bucharest , Romania , Phone: +4 021 318 0719, Email:"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorina C.","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Carol Davila University of Medicine and Pharmacy , Bucharest , Romania"},{"name":"Department of Endocrinology , Diabetes and Metabolic Disorders, Elias University Hospital , Bucharest , Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana M.","family":"Lambrescu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Carol Davila University of Medicine and Pharmacy , Bucharest , Romania"},{"name":"Department of Endocrinology , Diabetes and Metabolic Disorders, Elias University Hospital , Bucharest , Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lavinia","family":"Stejereanu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Carol Davila University of Medicine and Pharmacy , Bucharest , Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Zaharia","sequence":"additional","affiliation":[{"name":"Department of Paediatric Bone Marrow Transplantation , Fundeni Hospital , Bucharest , Romania"},{"name":"Department of Pediatrics , Carol Davila University of Medicine and Pharmacy , Bucharest , Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Colita","sequence":"additional","affiliation":[{"name":"Department of Paediatric Bone Marrow Transplantation , Fundeni Hospital , Bucharest , Romania"},{"name":"Department of Pediatrics , Carol Davila University of Medicine and Pharmacy , Bucharest , Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Fica","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Carol Davila University of Medicine and Pharmacy , Bucharest , Romania"},{"name":"Department of Endocrinology , Diabetes and Metabolic Disorders, Elias University Hospital , Bucharest , Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2018,6,23]]},"reference":[{"key":"2023040101280980694_j_jpem-2018-0020_ref_001_w2aab3b7c33b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror, ML, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;363:2091\u2013101.","DOI":"10.1056\/NEJMoa1004383"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_002_w2aab3b7c33b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005;105:4215\u201322.","DOI":"10.1182\/blood-2005-01-0035"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_003_w2aab3b7c33b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Schechter T, Pole JD, Darmawikarta D, Doyle J, Ali M, et al. Late mortality after hematopoietic SCT for a childhood malignancy. Bone Marrow Transplant 2013;48:1291\u20135.","DOI":"10.1038\/bmt.2013.64"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_004_w2aab3b7c33b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Parsons SK, Phipps S, Sung L, Baker KS, Pulsipher MA, et al. NCI, NHLBI\/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: health-related quality of life, functional, and neurocognitive outcomes. Biol Blood Marrow Transplant 2012;18:162\u201371.","DOI":"10.1016\/j.bbmt.2011.12.501"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_005_w2aab3b7c33b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Michel G, Bordigoni P, Simeoni MC, Curtillet C, Hoxsa S, et al. Health status and quality of life in long-term survivors of childhood leukaemia: the impact of haematopoietic stem cell transplantation. Bone Marrow Transplant 2007;40:897\u2013904.","DOI":"10.1038\/sj.bmt.1705821"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_006_w2aab3b7c33b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol 2015;2:91\u2013100.","DOI":"10.1016\/S2352-3026(15)00028-9"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_007_w2aab3b7c33b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Dvorak CC, Gracia CR, Sanders JE, Cheng EY, Baker KS, et al. NCI, NHLBI\/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, and reproductive risks. Biol Blood Marrow Transplant 2011;17:1725\u201338.","DOI":"10.1016\/j.bbmt.2011.10.006"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_008_w2aab3b7c33b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Orio F, Muscogiuri G, Palomba S, Serio B, Sessa M, et al. Endocrinopathies after allogeneic and autologous transplantation of hematopoietic stem cells. Scientific World J 2014;2014:282147.","DOI":"10.1155\/2014\/282147"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_009_w2aab3b7c33b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Gokcebay DG, Azik F, Bayram C, Erdem AY, Fettah A, et al. Evaluation of endocrine and metabolic dysfunctions after hematopoietic stem cell transplantation in children: a study from Turkey. J Pediatr Endocrinol Metab 2017;30:683\u201391.","DOI":"10.1515\/jpem-2016-0306"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_010_w2aab3b7c33b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Savas-Erdeve S, Berberoglu M, Siklar Z, Hacihamdioglu B, Ocal G, et al. Primary adrenal insufficiency in a child after busulfan and cyclophosphamide-based conditioning for hematopoietic stem cell transplantation. J Pediatr Endocrinol Metab 2011;24:853\u20135.","DOI":"10.1515\/JPEM.2011.131"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_011_w2aab3b7c33b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Cho WK, Lee JW, Chung NG, Jung MH, Cho B, et al. Primary ovarian dysfunction after hematopoietic stem cell transplantation during childhood: busulfan-based conditioning is a major concern. J Pediatr Endocrinol Metab 2011;24:1031\u20135.","DOI":"10.1515\/JPEM.2011.339"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_012_w2aab3b7c33b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Toubert M-E, Soci\u00e9 G, Gluckman E, Aractingi S, Esp\u00e9rou H, et al. Short- and long-term follow-up of thyroid dysfunction after allogeneic bone marrow transplantation without the use of preparative total body irradiation. Br J Haematol 1997;98:453\u20137.","DOI":"10.1046\/j.1365-2141.1997.2433060.x"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_013_w2aab3b7c33b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Schulte C, Reinhardt W, Beelen D, Mann K, Schaefer U. Low T3-syndrome and nutritional status as prognostic factors in patients undergoing bone marrow transplantation. Bone Marrow Transplant 1998;22:1171\u20138.","DOI":"10.1038\/sj.bmt.1701502"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_014_w2aab3b7c33b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Ishiguro H, Yasuda Y, Tomita Y, Shinagawa T, Shimizu T. Long-term follow-up of thyroid function in patients who received bone marrow transplantation during childhood and adolescence. J Clin Endocrinol Metab 2004;89:5981\u20136.","DOI":"10.1210\/jc.2004-0836"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_015_w2aab3b7c33b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Oudin C, Auguier P, Bertrand Y, Chastagner P, Kanold J, et al. Late thyroid complications in survivors of childhood acute leukemia. An L.E.A. study. Haematologica 2016;101:747\u201356.","DOI":"10.3324\/haematol.2015.140053"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_016_w2aab3b7c33b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Sanders JE, Hoffmeister PA, Woolfrey AE, Carpenter PA, Storer BE, et al. Thyroid function following hematopoietic cell transplantation in children: 30 years\u2019 experience. Blood 2009;113:306\u20138.","DOI":"10.1182\/blood-2008-08-173005"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_017_w2aab3b7c33b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Slatter MA, Gennery AR, Cheetham TD, Bhattacharya A, Crooks BN, et al. Thyroid dysfunction after bone marrow transplantation for primary immunodeficiency without the use of total body irradiation in conditioning. Bone Marrow Transplant 2004;33:949\u201353.","DOI":"10.1038\/sj.bmt.1704456"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_018_w2aab3b7c33b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Al-Fiar FZ, Colwill R, Lipton JH, Fyles G, Spaner D, et al. Abnormal thyroid stimulating hormone (TSH) levels in adults following allogeneic bone marrow transplants. Bone Marrow Transplant 1997;19:1019\u201322.","DOI":"10.1038\/sj.bmt.1700771"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_019_w2aab3b7c33b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Ayd\u0131ner \u00d6, Karako\u00e7 Ayd\u0131ner E, Akp\u0131nar \u0130, Turan S, Bereket A. Normative data of thyroid volume-ultrasonographic evaluation of 422 subjects aged 0\u201355 years. J Clin Res Pediatr Endocrinol 2015;7:98\u2013101.","DOI":"10.4274\/jcrpe.1818"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_020_w2aab3b7c33b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Chow EJ, Liu W, Srivastava K, Leisenring WM, Hayashi RJ, et al. Differential effects of radiotherapy on growth and endocrine function among acute leukemia survivors: a childhood cancer survivor study report. Pediatr Blood Cancer 2013;60:110\u20135.","DOI":"10.1002\/pbc.24198"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_021_w2aab3b7c33b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Afify Z, Shaw PJ, Clavano-Harding A, Cowell CT. Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan\/cyclophosphamide. Bone Marrow Transplant 2000;25:1087\u201392.","DOI":"10.1038\/sj.bmt.1702384"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_022_w2aab3b7c33b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Petryk A, Kanakatti Shankar R, Giri N, Hollenberg AN, Rutter MM, et al. Endocrine disorders in Fanconi anemia: recommendations for screening and treatment. J Clin Endocrinol Metab 2015;100:803\u201311.","DOI":"10.1210\/jc.2014-4357"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_023_w2aab3b7c33b1b6b1ab2b1c23Aa","unstructured":"De Sanctis V, Soliman A, Candini G, Campisi S, Anastasi S, et al. High prevalence of central hypothyroidism in adult patients with \u03b2-thalassemia major. Georgian Med News 2013;222:88\u201394."},{"key":"2023040101280980694_j_jpem-2018-0020_ref_024_w2aab3b7c33b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Keilholz U, Max R, Scheibenbogen C, W\u00fcster C, K\u00f6rbling M, et al. Endocrine function and bone metabolism 5 years after autologous bone marrow\/blood-derived progenitor cell transplantation. Cancer 1997;79:1617\u201322.","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1617::AID-CNCR27>3.0.CO;2-#"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_025_w2aab3b7c33b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Vialettes B, Maraninchi D, San Marco MP, Birg F, Stoppa AM, et al. Autoimmune polyendocrine failure-type 1 (insulin-dependent) diabetes mellitus and hypothyroidism after allogeneic bone marrow transplantation in a patient with lymphoblastic leukemia. Diabetologia 1993;36:541\u20136.","DOI":"10.1007\/BF02743271"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_026_w2aab3b7c33b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"McLeod DS, Watters KF, Carpenter AD, Ladenson PW, Cooper DS, et al. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab 2012;97:2682\u201392.","DOI":"10.1210\/jc.2012-1083"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_027_w2aab3b7c33b1b6b1ab2b1c27Aa","unstructured":"De Simone M, Olioso P, Di Bartolomeo P, Cheng PO, Lee V, et al. Growth and endocrine function following bone marrow transplantation for thalassemia. Bone Marrow Transplant 1995;5:227\u201333."},{"key":"2023040101280980694_j_jpem-2018-0020_ref_028_w2aab3b7c33b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Bailey H, Kappy M, Giller R, Gralla J. Time-course and risk factors of hypothyroidism following allogeneic hematopoietic stem cell transplantation (HSCT) in children conditioned with fractionated total body irradiation. Pediatr Blood Cancer 2008;51:405\u20139.","DOI":"10.1002\/pbc.21634"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_029_w2aab3b7c33b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Sa\u011f E, G\u00f6n\u00e7 N, Alika\u015fifo\u011flu A, Ku\u015fkonmaz B, U\u00e7kan D, et al. Hyperthyroidism after allogeneic hematopoietic stem cell transplantation: a report of four cases. J Clin Res Pediatr Endocrinol 2015;7:349\u201354.","DOI":"10.4274\/jcrpe.2295"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_030_w2aab3b7c33b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Savani B, Koklanaris E, Le Q, Shenoy A, Goodman S, et al. Prolonged chronic graft-versus-host disease is a risk factor for thyroid failure in long-term survivors after matched sibling donor stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2009;15:377\u201381.","DOI":"10.1016\/j.bbmt.2008.11.032"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_031_w2aab3b7c33b1b6b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"Aldouri MA, Ruggier R, Epstein O, Prentice HG. Adoptive transfer of hyperthyroidism and autoimmune thyroiditis following allogeneic bone marrow transplantation for chronic myeloid leukaemia. Br J Haematol 1990;74:118\u201320.","DOI":"10.1111\/j.1365-2141.1990.tb02548.x"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_032_w2aab3b7c33b1b6b1ab2b1c32Aa","doi-asserted-by":"crossref","unstructured":"Vardizer Y, Lupetti A, Vandelanotte S, Lankester AC, Wiersinga WM, et al. Graves\u2019 orbitopathy in a patient with adrenoleukodystrophy after bone marrow transplantation. Eur J Endocrinol 2009;161:369\u201373.","DOI":"10.1530\/EJE-08-0944"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_033_w2aab3b7c33b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Lee WY, Oh ES, Min CK, Kim DW, Lee JW, et al. Changes in autoimmune thyroid disease following allogeneic bone marrow transplantation. Bone Marrow Transplant 2001;28:63\u20136.","DOI":"10.1038\/sj.bmt.1703102"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_034_w2aab3b7c33b1b6b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Vantyghem MC, Cornillon J, Decanter C, Defrance F, Karrouz W, et al. Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation. Orphanet J Rare Disease 2014;29:162.","DOI":"10.1186\/s13023-014-0162-0"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_035_w2aab3b7c33b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Weetman A. Immune reconstitution syndrome and the thyroid. Best Practice Res Clin Endocrinol Metab 2009;23:693\u2013702.","DOI":"10.1016\/j.beem.2009.07.003"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_036_w2aab3b7c33b1b6b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"Cossburn M, Pace AA, Jones J, Ali R, Ingram G, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011;77:573\u20139.","DOI":"10.1212\/WNL.0b013e318228bec5"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_037_w2aab3b7c33b1b6b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"Williams KM, Dietzen D, Hassoun AA, Fennoy I, Bhatia M. Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease. Pediatr Blood Cancer 2014;61:2307\u20139.","DOI":"10.1002\/pbc.25102"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_038_w2aab3b7c33b1b6b1ab2b1c38Aa","doi-asserted-by":"crossref","unstructured":"Trinh T, Haridas AS, Sullivan TJ. Ocular findings in alemtuzumab (Campath-1H)-induced thyroid eye disease. Ophthalmic Plast Reconstr Surg 2016;32:128\u20139.","DOI":"10.1097\/IOP.0000000000000310"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_039_w2aab3b7c33b1b6b1ab2b1c39Aa","doi-asserted-by":"crossref","unstructured":"Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 2014;99:80\u20139.","DOI":"10.1210\/jc.2013-2201"},{"key":"2023040101280980694_j_jpem-2018-0020_ref_040_w2aab3b7c33b1b6b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"Au WY, Hawkins BR, Chan EY, Lie AK, Kung AW, et al. Association of the HLA A2-B46-DR9 haplotype with autoimmune thyroid dysfunction after bone marrow transplantation in Chinese patients. Br J Haematol 2001;115:660\u20133.","DOI":"10.1046\/j.1365-2141.2001.03197.x"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jpem.2018.31.issue-8\/jpem-2018-0020\/jpem-2018-0020.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2018-0020\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2018-0020\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T20:14:09Z","timestamp":1680380049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2018-0020\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,23]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,7,9]]},"published-print":{"date-parts":[[2018,8,28]]}},"alternative-id":["10.1515\/jpem-2018-0020"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2018-0020","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"type":"electronic","value":"2191-0251"},{"type":"print","value":"0334-018X"}],"subject":[],"published":{"date-parts":[[2018,6,23]]}}}